{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:05:33Z","timestamp":1779159933649,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T00:00:00Z","timestamp":1438992000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s10620-015-3838-y","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T07:53:52Z","timestamp":1438934032000},"page":"99-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn\u2019s Disease"],"prefix":"10.1007","volume":"61","author":[{"given":"Ken","family":"Sugimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ikeya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Hanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,8]]},"reference":[{"key":"3838_CR1","unstructured":"Bischoff SC, Herrmann A, G\u00f6ke M, Manns MP, von zur M\u00fchlen A, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol. 1997;92:1157\u20131163."},{"key":"3838_CR2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.amjmed.2009.01.022","volume":"122","author":"T Ali","year":"2009","unstructured":"Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122:599\u2013604.","journal-title":"Am J Med"},{"key":"3838_CR3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1590\/S0004-27302006000400004","volume":"50","author":"EM Lewiecki","year":"2006","unstructured":"Lewiecki EM, Borges JL. Bone density testing in clinical practice. Arq Bras Endocrinol Metabol. 2006;50:586\u2013595.","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"3838_CR4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785\u2013795.","journal-title":"JAMA"},{"key":"3838_CR5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/jbmr.5650110602","volume":"11","author":"HK Genant","year":"1996","unstructured":"Genant HK, Engelke K, Fuerst T, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res. 1996;11:707\u2013730.","journal-title":"J Bone Miner Res"},{"key":"3838_CR6","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/oxfordjournals.ndt.a027457","volume":"11","author":"MM Couttenye","year":"1996","unstructured":"Couttenye MM, D\u2019Haese PC, Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transpl. 1996;11:1065\u20131072.","journal-title":"Nephrol Dial Transpl"},{"key":"3838_CR7","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1359\/jbmr.2000.15.3.594","volume":"15","author":"R Eastell","year":"2000","unstructured":"Eastell R, Mallinak N, Weiss S, et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res. 2000;15:594\u2013598.","journal-title":"J Bone Miner Res"},{"key":"3838_CR8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(00)05135-7","volume":"357","author":"P Szulc","year":"2001","unstructured":"Szulc P, Meunier PJ. Is vitamin K deficiency a risk factor for osteoporosis in Crohn\u2019s disease? Lancet. 2001;357:1995\u20131996.","journal-title":"Lancet"},{"key":"3838_CR9","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/ibd.20947","volume":"15","author":"P Miheller","year":"2009","unstructured":"Miheller P, Muzes G, Hritz I, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn\u2019s disease patients. Inflamm Bowel Dis. 2009;15:1656\u20131662.","journal-title":"Inflamm Bowel Dis"},{"key":"3838_CR10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/gut.40.3.313","volume":"40","author":"J Jahnsen","year":"1997","unstructured":"Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn\u2019s disease but not in patients with ulcerative colitis: a population based study. Gut. 1997;40:313\u2013319.","journal-title":"Gut"},{"key":"3838_CR11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0016-5085(94)90227-5","volume":"107","author":"S Ghosh","year":"1994","unstructured":"Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn\u2019s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994;107:1031\u20131039.","journal-title":"Gastroenterology"},{"key":"3838_CR12","doi-asserted-by":"crossref","unstructured":"Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn\u2019s disease and ulcerative colitis. J Intern Med. 2000;247:63\u201370.","DOI":"10.1046\/j.1365-2796.2000.00582.x"},{"key":"3838_CR13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.cgh.2012.10.022","volume":"11","author":"LE Targownik","year":"2013","unstructured":"Targownik LE, Bernstein CN, Nugent Z, Leslie WD. Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis. Clin Gastroenterol Hepatol. 2013;11:278\u2013285.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3838_CR14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4158\/EP.12.6.622","volume":"12","author":"BP Sinnott","year":"2006","unstructured":"Sinnott BP, Licata AA. Assessment of bone and mineral metabolism in inflammatory bowel disease: case series and review. Endocr Pract. 2006;12:622\u2013629.","journal-title":"Endocr Pract"},{"key":"3838_CR15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1542-3565(03)00185-X","volume":"1","author":"EV Loftus Jr","year":"2003","unstructured":"Loftus EV Jr, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ 3rd. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003;1:465\u2013473.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3838_CR16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/ajcn\/54.3.548","volume":"54","author":"GA Leichtmann","year":"1991","unstructured":"Leichtmann GA, Bengoa JM, Bolt MJ, Sitrin MD. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn\u2019s disease and intestinal resection. Am J Clin Nutr. 1991;54:548\u2013552.","journal-title":"Am J Clin Nutr"},{"key":"3838_CR17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/MIB.0b013e31828075a7","volume":"19","author":"N Azzopardi","year":"2013","unstructured":"Azzopardi N, Ellul P. Risk factors for osteoporosis in Crohn\u2019s disease: infliximab, corticosteroids, body mass index, and age of onset. Inflamm Bowel Dis. 2013;19:1173\u20131178.","journal-title":"Inflamm Bowel Dis"},{"key":"3838_CR18","doi-asserted-by":"crossref","first-page":"V1","DOI":"10.1136\/gut.2004.043372","volume":"53","author":"MJ Carter","year":"2004","unstructured":"Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53:V1\u2013V16.","journal-title":"Gut"},{"key":"3838_CR19","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/gut.2003.036657","volume":"53","author":"MT Abreu","year":"2004","unstructured":"Abreu MT, Kantorovich V, Vasiliauskas EA, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn\u2019s disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut. 2004;53:1129\u20131136.","journal-title":"Gut"},{"key":"3838_CR20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.nut.2010.10.021","volume":"27","author":"S Nakajima","year":"2011","unstructured":"Nakajima S, Iijima H, Egawa S, et al. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease. Nutrition. 2011;27:1023\u20131028.","journal-title":"Nutrition"},{"key":"3838_CR21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1365-2036.2006.02835.x","volume":"23","author":"J Gilman","year":"2006","unstructured":"Gilman J, Shanahan F, Cashman KD. Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn\u2019s disease and ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1007\u20131016.","journal-title":"Aliment Pharmacol Ther"},{"key":"3838_CR22","doi-asserted-by":"crossref","first-page":"197S","DOI":"10.1016\/8756-3282(95)00502-1","volume":"18","author":"BL Riggs","year":"1996","unstructured":"Riggs BL, Melton LJ 3rd, O\u2019Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone. 1996;18:197S\u2013201S.","journal-title":"Bone"},{"key":"3838_CR23","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1359\/jbmr.1999.14.9.1614","volume":"14","author":"P Garnero","year":"1999","unstructured":"Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4\u00a0years: the OFELY study. J Bone Miner Res. 1999;14:1614\u20131621.","journal-title":"J Bone Miner Res"},{"key":"3838_CR24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9343(96)00387-7","volume":"102","author":"CH Chesnut 3rd","year":"1997","unstructured":"Chesnut CH 3rd, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med. 1997;102:29\u201337.","journal-title":"Am J Med"},{"key":"3838_CR25","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","volume":"18","author":"R Eastell","year":"2003","unstructured":"Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051\u20131056.","journal-title":"J Bone Miner Res"},{"key":"3838_CR26","doi-asserted-by":"crossref","unstructured":"Ciucci T, Ib\u00e1\u00f1ez L, Boucoiran A, et al. Bone marrow Th17 TNF\u03b1 cells induce osteoclast differentiation, and link bone destruction to IBD. Gut. 2014. doi: 10.1136\/gutjnl-2014-306947 .","DOI":"10.1136\/gutjnl-2014-306947"},{"key":"3838_CR27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2036.2004.02152.x","volume":"20","author":"N Franchimont","year":"2004","unstructured":"Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn\u2019s disease. Aliment Pharmacol Ther. 2004;20:607\u2013614.","journal-title":"Aliment Pharmacol Ther"},{"key":"3838_CR28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2036.2004.02097.x","volume":"20","author":"BM Ryan","year":"2004","unstructured":"Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn\u2019s disease: a prospective study. Aliment Pharmacol Ther. 2004;20:851\u2013857.","journal-title":"Aliment Pharmacol Ther"},{"key":"3838_CR29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.mcg.0000190762.80615.d4","volume":"40","author":"MT Abreu","year":"2006","unstructured":"Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn\u2019s disease. J Clin Gastroenterol. 2006;40:55\u201363.","journal-title":"J Clin Gastroenterol"},{"key":"3838_CR30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000091299","volume":"24","author":"P Miheller","year":"2006","unstructured":"Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z. Infliximab therapy improves the bone metabolism in fistulizing Crohn\u2019s disease. Dig Dis. 2006;24:201\u2013206.","journal-title":"Dig Dis"},{"key":"3838_CR31","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/j.1572-0241.2005.50219.x","volume":"100","author":"M Bernstein","year":"2005","unstructured":"Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn\u2019s disease. Am J Gastroenterol. 2005;100:2031\u20132035.","journal-title":"Am J Gastroenterol"},{"key":"3838_CR32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/gut.28.4.410","volume":"28","author":"JE Compston","year":"1987","unstructured":"Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut. 1987;28:410\u2013415.","journal-title":"Gut"},{"key":"3838_CR33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/gut.40.2.228","volume":"40","author":"I Bjarnason","year":"1997","unstructured":"Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228\u2013233.","journal-title":"Gut"},{"key":"3838_CR34","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1572-0241.1998.468_q.x","volume":"93","author":"RD Pollak","year":"1998","unstructured":"Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93:1483\u20131490.","journal-title":"Am J Gastroenterol"},{"key":"3838_CR35","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/BF01296010","volume":"37","author":"F Pigot","year":"1992","unstructured":"Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci. 1992;37:1396\u20131403.","journal-title":"Dig Dis Sci"},{"key":"3838_CR36","doi-asserted-by":"crossref","unstructured":"Robinson RJ, al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn\u2019s disease. Dig Dis Sci. 1998;43:2500\u20132506.","DOI":"10.1023\/A:1026650719552"},{"key":"3838_CR37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cgh.2013.08.024","volume":"12","author":"J Melek","year":"2014","unstructured":"Melek J, Sakuraba A. Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review. Clin Gastroenterol Hepatol. 2014;12:32\u201344.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-3838-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-015-3838-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-3838-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:26:49Z","timestamp":1567038409000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-015-3838-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,8]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["3838"],"URL":"https:\/\/doi.org\/10.1007\/s10620-015-3838-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,8]]}}}